1. 1186. Cefazolin inoculum effect predicts reduced susceptibility to other antibiotics and patient outcomes in MSSA endovascular infections. (31st December 2020) Authors: Smelter, Dan; McCrone, Sue; Rose, Warren Journal: Open forum infectious diseases Issue: Volume 7:Number 1(2020) Supplement Page Start: S617 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Instability and mutation impact on C-MyBP-C FNIII domain suggests a previously unappreciated functional relevance. (November 2018) Authors: Smelter, Dan; de Lange, Willem; Carter Ralphe, J. Journal: Journal of molecular and cellular cardiology Issue: Volume 124(2018) Page Start: 112 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Potent Activity of Ertapenem Plus Cefazolin Within Staphylococcal Biofilms: A Contributing Factor in the Treatment of Methicillin-Susceptible Staphylococcus aureus Endocarditis. (23rd March 2022) Authors: Gilbertie, Jessica; Ulloa, Erlinda R; Daiker, Jennifer C; Nguyen, Khanh; Smelter, Dan; Rose, Warren; Geriak, Matthew; Schnabel, Lauren V; Nizet, Victor; Sakoulas, George Journal: Open forum infectious diseases Issue: Volume 9:Number 5(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The W792R mutation in cardiac myosin binding protein-C reduces the C6 FnIII domain stability and causes hypertrophic cardiomyopathy through haploinsufficiency. (November 2017) Authors: Smelter, Dan; de Lange, Willem; Carter Ralphe, J. Journal: Journal of molecular and cellular cardiology Issue: Volume 112(2017) Page Start: 141 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗